Your Study Included Diet and Exercise. Say So.

What does FTC Example 8 require an advertiser to disclose?

Example 8 requires an advertiser to tell readers, inside the ad itself, that a supplement's clinical results depended on diet and exercise as well as the product. The example describes a supplement citing a placebo-controlled trial in which subjects lost 12 pounds over eight weeks — a trial where, per FTC's Health Products Compliance Guidance, "both the control and test subjects engaged in regular exercise and followed a restricted-calorie diet as part of the study regimen." FTC's conclusion is not hedged: "The ad should make clear that users of the supplement also will need to reduce calories and engage in regular exercise to achieve similar results."

That's the whole rule, and almost no landing page in this niche follows it.

We checked this against the full 2022 guidance rather than a secondhand summary, because Example 8 compresses easily into "disclose your study" and loses its actual trigger. The trigger is a diet or exercise arm inside the trial design — not diet or exercise mentioned somewhere in a background paragraph, and not a general lifestyle disclaimer bolted onto an unrelated study. If your landing page cites a number from a clinical trial, you need to know whether that trial controlled what subjects ate before you can write the headline honestly.

Why does almost every supplement RCT include a diet arm?

Almost every supplement RCT includes a diet arm because isolating a pill's own effect requires controlling what subjects eat, and few sponsors will run a trial where subjects eat freely. Weight is downstream of calories in and calories out; a researcher who wants a clean signal has to hold one of those variables steady, and the ethical, practical way to do that is to put both the treatment and placebo groups on the same restricted diet and exercise plan. That design answers the scientific question. It does not answer the marketing question of what the pill alone does.

This is also why FTC treats a purely metabolic endpoint as insufficient proof of weight loss on its own. As a federal court held, in a holding FTC's guidance cites directly, "a study examining metabolic endpoints cannot determine whether weight loss will also occur." A study can show a supplement raised thermogenesis in a lab setting and still tell you nothing about whether a customer drops a single pound, because the bridge from metabolic marker to scale weight has never been established for that formula.

FTC's guidance makes a second, related point that most compliance checklists skip: two positive studies do not survive one well-conducted null study. Example 30 in the same guidance describes an advertiser with two controlled trials showing a modest six-week fat loss, sitting against an equally well-controlled 12-week study showing no significant difference — and concludes the claim is unsubstantiated when weighed as a whole. A cherry-picked citation from a favorable arm of a mixed trial record fails this totality test even before the diet-disclosure question comes up.

How does omitting the diet arm change the claim consumers receive?

Omitting the diet arm converts an honest study citation into one of the seven claims FTC has pre-labeled as presumptively false. The Gut Check reference guide states an ad is deceptive if it implies a product "causes substantial weight loss no matter what or how much the consumer eats" — and a headline number lifted from a diet-controlled trial, presented without that context, implies exactly this to a reasonable reader.

The read a consumer takes away is not subtle. See "lost 12 pounds in 8 weeks," and absent any diet or exercise caveat, most people assume the pill did that work alone. What counts as substantial weight loss to the FTC is defined with a numeric threshold for exactly this reason — a pound a week for more than four weeks, or more than 15 pounds total — and FTC's own guide notes that advertisers can convey the same false message through dress-size or inch references, without a number at all.

The gap between the study's actual claim and the ad's implied claim is the entire violation. The study says: 1,200-calorie diet plus daily walking plus supplement produced a 12-pound loss. The ad, stripped of the diet arm, says: supplement produced a 12-pound loss. Those are two different products being sold, and only one of them was tested.

Where on the page does the disclosure need to appear?

The disclosure has to sit adjacent to the claim it qualifies, in a size and prominence comparable to the claim itself — not in a footer, and not on a separate page. FTC's Example 41 makes this concrete: a before-and-after ad quoted a woman who lost 16 pounds in eight weeks, with a fine-print asterisk reading "these results are not typical," against a study that averaged only four pounds over placebo. FTC called the disclosure inadequate and prescribed the fix directly — a prominent, adjacent statement of what the study actually showed.

We found no FTC or FDA document specifying a minimum font-size ratio between claim and disclosure. What both agencies specify instead is proximity and comparable weight — the disclosure has to travel with the claim, not trail behind it in different type.

Does 'when combined with diet and exercise' in small type satisfy it?

No — small type alone does not satisfy the rule, even when the wording is technically accurate. FTC's Example 14 addresses a disclaimer that is "directly contradictory" to the express claim above it, concluding the disclaimer is "ineffective to negate" that claim regardless of where it sits. Example 15 goes further, rejecting a fine-print "no clinical study has been performed" line buried in Terms and Conditions as a cure for a false scientific-proof claim built from lab coats and clinical-sounding language.

Worth separating two things that get conflated on most compliance checklists: the DSHEA disclaimer required under 21 CFR 101.93(c) — "This statement has not been evaluated by the Food and Drug Administration..." — is an FDA labeling requirement, and it satisfies FDA. It does nothing for the FTC's Example 8 obligation. An advertiser can run the DSHEA disclaimer correctly and still be deceptive under FTC's separate substantiation standard for failing to disclose the study's diet arm. The two disclosures answer two different regulators' questions, and printing one does not excuse skipping the other.

How does this interact with the no-diet-no-exercise Gut Check claim?

The two rules overlap but are not the same rule. Gut Check's seven presumptively false claims — including that a product "causes weight loss of two pounds or more a week for a month or more without dieting or exercise" — target an affirmative promise of effortless results. Example 8's disclosure duty is broader: it applies even to an honest ad that never promises effortless loss but still cites a diet-assisted trial without saying so.

Both platforms have independently built enforcement around the same failure mode. Google's Unreliable Claims Rule for Diet Offers bans claims that entice with an improbable result as the likely outcome, naming little-effort weight-loss claims specifically. Meta's weight-loss ad rules separately restrict clickbait creative promising specific outcomes within a set timeframe without disclaimers. A claim can clear FDA's structure/function test, still violate FTC's Example 8, and still get an account flagged on either platform — three separate failure points stacked on the same missing sentence.

What should a buyer ask an advertiser for before running the study?

Ask for the full protocol before you run a single dollar of media against a study-backed claim. A headline number without the methods section tells you nothing about what the ad is actually allowed to say.

• Was the trial placebo-controlled, and were both arms placed on the same diet and exercise regimen — or was diet uncontrolled in one or both arms?
• Is this the only trial on the formula, or does the advertiser have other trials — including any null or negative ones — that a totality-of-evidence review under Example 30 would have to weigh?
• What was the actual average result across all subjects, not just the best individual case, since Example 41's typicality standard is triggered by claims of two pounds a week or more, or 15 pounds total?
• Does the landing page state the diet-and-exercise condition adjacent to the headline claim, in comparable type, or only in a footer or linked policy page?
• Is the study on the finished formula at the marketed dose, or on an individual ingredient — since FTC treats ingredient-level evidence as insufficient to substantiate a formula-level claim in this vertical?

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, FDA Never Defined Detox. That Is the Real Exposure., Capsule vs Cream: One Sentence, Two Verdicts, The Aging Claims FDA Put on the Non-Disease List, Telomeres and Gene Activity: Two Charged Mechanisms, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.